Donika Plyku1, Esther Mena1, Steven P Rowe1, Martin A Lodge1, Zsolt Szabo1, Steve Y Cho1,2, Martin G Pomper1,3, George Sgouros1,4, Robert F Hobbs5,6. 1. The Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. 2. Department of Radiology, School of Medicine and Public Health, University of Wisconsin, CRB II 4M.60, 1550 Orleans St., Baltimore, MD, 21287, USA. 3. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA. 4. Department of Radiation Oncology, School of Medicine, Johns Hopkins University, CRB II 4M.60, 1550 Orleans St., Baltimore, MD, USA. 5. The Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. rhobbs3@jhmi.edu. 6. Department of Radiation Oncology, School of Medicine, Johns Hopkins University, CRB II 4M.60, 1550 Orleans St., Baltimore, MD, USA. rhobbs3@jhmi.edu.
Abstract
PURPOSE: Prostate-specific membrane antigen (PSMA), a type-II integral membrane protein highly expressed in prostate cancer, has been extensively used as a target for imaging and therapy. Among the available PET radiotracers, the low molecular weight agents that bind to PSMA are proving particularly effective. We present the dosimetry results for 18F-DCFPyL in nine patients with metastatic prostate cancer. METHODS: Nine patients were imaged using sequential PET/CT scans at approximately 1, 12, 35 and 70 min, and a final PET/CT scan at approximately 120 min after intravenous administration of 321 ± 8 MBq (8.7 ± 0.2 mCi) of18F-DCFPyL. Time-integrated-activity coefficients were calculated and used as input in OLINDA/EXM software to obtain dose estimates for the majority of the major organs. The absorbed doses (AD) to the eye lens and lacrimal glands were calculated using Monte-Carlo models based on idealized anatomy combined with patient-specific volumes and activity from the PET/CT scans. Monte-Carlo based models were also developed for calculation of the dose to two major salivary glands (parotid and submandibular) using CT-based patient-specific gland volumes. RESULTS: The highest calculated mean AD per unit administered activity of 18F was found in the lacrimal glands, followed by the submandibular glands, kidneys, urinary bladder wall, and parotid glands. The S-values for the lacrimal glands to the eye lens (0.42 mGy/MBq h), the tear film to the eye lens (1.78 mGy/MBq h) and the lacrimal gland self-dose (574.10 mGy/MBq h) were calculated. Average S-values for the salivary glands were 3.58 mGy/MBq h for the parotid self-dose and 6.78 mGy/MBq h for the submandibular self-dose. The resultant mean effective dose of 18F-DCFPyL was 0.017 ± 0.002 mSv/MBq. CONCLUSIONS: 18F-DCFPyL dosimetry in nine patients was obtained using novel models for the lacrimal and salivary glands, two organs with potentially dose-limiting uptake for therapy and diagnosis which lacked pre-existing models.
PURPOSE:Prostate-specific membrane antigen (PSMA), a type-II integral membrane protein highly expressed in prostate cancer, has been extensively used as a target for imaging and therapy. Among the available PET radiotracers, the low molecular weight agents that bind to PSMA are proving particularly effective. We present the dosimetry results for 18F-DCFPyL in nine patients with metastatic prostate cancer. METHODS: Nine patients were imaged using sequential PET/CT scans at approximately 1, 12, 35 and 70 min, and a final PET/CT scan at approximately 120 min after intravenous administration of 321 ± 8 MBq (8.7 ± 0.2 mCi) of18F-DCFPyL. Time-integrated-activity coefficients were calculated and used as input in OLINDA/EXM software to obtain dose estimates for the majority of the major organs. The absorbed doses (AD) to the eye lens and lacrimal glands were calculated using Monte-Carlo models based on idealized anatomy combined with patient-specific volumes and activity from the PET/CT scans. Monte-Carlo based models were also developed for calculation of the dose to two major salivary glands (parotid and submandibular) using CT-based patient-specific gland volumes. RESULTS: The highest calculated mean AD per unit administered activity of 18F was found in the lacrimal glands, followed by the submandibular glands, kidneys, urinary bladder wall, and parotid glands. The S-values for the lacrimal glands to the eye lens (0.42 mGy/MBq h), the tear film to the eye lens (1.78 mGy/MBq h) and the lacrimal gland self-dose (574.10 mGy/MBq h) were calculated. Average S-values for the salivary glands were 3.58 mGy/MBq h for the parotid self-dose and 6.78 mGy/MBq h for the submandibular self-dose. The resultant mean effective dose of 18F-DCFPyL was 0.017 ± 0.002 mSv/MBq. CONCLUSIONS:18F-DCFPyL dosimetry in nine patients was obtained using novel models for the lacrimal and salivary glands, two organs with potentially dose-limiting uptake for therapy and diagnosis which lacked pre-existing models.
Entities:
Keywords:
18F; Dosimetry; Monte-Carlo modeling; PET; PSMA; Prostate cancer
Authors: Ying Chen; Mrudula Pullambhatla; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Srinivasan Senthamizhchelvan; George Sgouros; Ronnie C Mease; Martin G Pomper Journal: Clin Cancer Res Date: 2011-10-31 Impact factor: 12.531
Authors: Zsolt Szabo; Esther Mena; Steven P Rowe; Donika Plyku; Rosa Nidal; Mario A Eisenberger; Emmanuel S Antonarakis; Hong Fan; Robert F Dannals; Ying Chen; Ronnie C Mease; Melin Vranesic; Akrita Bhatnagar; George Sgouros; Steve Y Cho; Martin G Pomper Journal: Mol Imaging Biol Date: 2015-08 Impact factor: 3.488
Authors: Diana A Tamboli; Matheson A Harris; Jeffery P Hogg; Tony Realini; Jennifer A Sivak-Callcott Journal: Ophthalmic Plast Reconstr Surg Date: 2011 Nov-Dec Impact factor: 1.746
Authors: Ken Herrmann; Christina Bluemel; Martina Weineisen; Margret Schottelius; Hans-Jürgen Wester; Johannes Czernin; Uta Eberlein; Seval Beykan; Constantin Lapa; Hubertus Riedmiller; Markus Krebs; Saskia Kropf; Andreas Schirbel; Andreas K Buck; Michael Lassmann Journal: J Nucl Med Date: 2015-04-16 Impact factor: 10.057
Authors: Shozo Okamoto; Anne Thieme; Jakob Allmann; Calogero D'Alessandria; Tobias Maurer; Margitta Retz; Robert Tauber; Matthias M Heck; Hans-Juergen Wester; Nagara Tamaki; Wolfgang P Fendler; Ken Herrmann; Christian H Pfob; Klemens Scheidhauer; Markus Schwaiger; Sibylle Ziegler; Matthias Eiber Journal: J Nucl Med Date: 2016-09-22 Impact factor: 10.057
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Sangeeta Ray Banerjee; Vivek Kumar; Ala Lisok; Donika Plyku; Zora Nováková; Mary Brummet; Bryan Wharram; Cyril Barinka; Robert Hobbs; Martin G Pomper Journal: J Nucl Med Date: 2018-09-20 Impact factor: 10.057
Authors: Etienne Rousseau; Don Wilson; Frédéric Lacroix-Poisson; Andra Krauze; Kim Chi; Martin Gleave; Michael McKenzie; Scott Tyldesley; S Larry Goldenberg; François Bénard Journal: J Nucl Med Date: 2019-04-12 Impact factor: 10.057
Authors: Marcin Czarniecki; Esther Mena; Liza Lindenberg; Marek Cacko; Stephanie Harmon; Jan Philipp Radtke; Frederick Giesel; Baris Turkbey; Peter L Choyke Journal: Transl Androl Urol Date: 2018-10
Authors: Rudolf A Werner; Thorsten Derlin; Constantin Lapa; Sara Sheikbahaei; Takahiro Higuchi; Frederik L Giesel; Spencer Behr; Alexander Drzezga; Hiroyuki Kimura; Andreas K Buck; Frank M Bengel; Martin G Pomper; Michael A Gorin; Steven P Rowe Journal: Theranostics Date: 2020-01-01 Impact factor: 11.556
Authors: Leonie Beyer; Astrid Gosewisch; Simon Lindner; Friederike Völter; Lena M Mittlmeier; Reinhold Tiling; Matthias Brendel; Clemens C Cyran; Marcus Unterrainer; Johannes Rübenthaler; Christoph J Auernhammer; Christine Spitzweg; Guido Böning; F J Gildehaus; Klaus Jurkschat; Carmen Wängler; Björn Wängler; Ralf Schirrmacher; Vera Wenter; Andrei Todica; Peter Bartenstein; Harun Ilhan Journal: Eur J Nucl Med Mol Imaging Date: 2021-04-29 Impact factor: 9.236